Condition
Measles Vaccine
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
60%
3 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 4 (3)
Trial Status
Completed3
Enrolling By Invitation1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT01644721Phase 4CompletedPrimary
Trial of Additional Measles Vaccine to Reduce Child Mortality
NCT01668745Phase 4CompletedPrimary
Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.
NCT04220671Phase 4Enrolling By InvitationPrimary
Measles Vaccination at Health System Contacts
NCT05154097UnknownPrimary
Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella)
NCT04468802Completed
Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?
Showing all 5 trials